Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Consolidated Net Income rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year increase of 13888.89%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Consolidated Net Income stood at $42.0 million, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Consolidated Net Income ranged from a high of $85.0 million in Q2 2023 and a low of -$329.0 million during Q4 2022
  • For the 4-year period, Indivior Pharmaceuticals' Consolidated Net Income averaged around -$5.8 million, with its median value being $45.0 million (2025).
  • Examining YoY changes over the last 5 years, Indivior Pharmaceuticals' Consolidated Net Income showed a top increase of 12066.87% in 2023 and a maximum decrease of 43880.6% in 2023.
  • Indivior Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$329.0 million in 2022, then skyrocketed by 120.67% to $68.0 million in 2023, then plummeted by 69.12% to $21.0 million in 2024, then soared by 100.0% to $42.0 million in 2025.
  • Its last three reported values are $42.0 million in Q3 2025, $18.0 million for Q2 2025, and $48.0 million during Q1 2025.